Almac discusses its investment in biocatalysis lauding cost and environmental benefits on OutsourcingPharma.com
November 23, 2010
Almac invests $4m in biocatalysis R&D, describing such technologies as the way forward for the cost efficient production of highly chiral APIs and intermediates.
Click here to listen to the podcast featuring Tom Moody, head of Almac’s biocatlaysis unit (Almac Sciences business unit).
The Almac Group offers a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs almost 3,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has officially gained full possession of its new $120m North American Headquarters which started in July 2008 and employees will relocate during the fall.
For more information on Almac, please visit www.almacgroup.com or email [email protected]